Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Ng K, Ciardiello F, Van Cutsem E, Yaeger R, Yoshino T, Desai J, Wasan HS, Alkuzweny B, Zhang X, Tabernero J, Kopetz S July 2, 2022 ESMO World GI 2022 Colorectal Cancer

Evaluating Age as a Factor for Survival and Quality of Life in Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer Treated With Encorafenib + Cetuximab ± Binimetinib: Subanalysis of BEACON CRC

View Presentation
Oral Presentation
Tabernero J, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan HS, Van Cutsem E, Ciardiello F, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chavira R, Usari T, Hahn E, Kopetz S September 12, 2022 ESMO 2022 Colorectal Cancer

BREAKWATER Safety Lead-In (SLI): Encorafenib (E) + Cetuximab (C) + Chemotherapy (Chemo) for BRAFV600E Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary
Oral Presentation
Kopetz S, Murphy DA, Pu J, Yaeger R, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Alkuzweny B, Xie T, Zhang X, Tabernero J September 12, 2022 ESMO 2022 Colorectal Cancer

Genomic Mechanisms of Acquired Resistance of Patients (pts) With BRAF V600E-Mutant (mt) Metastatic Colorectal Cancer (mCRC) Treated in the BEACON Study

View Presentation View Abstract Plain Language Summary
Poster
Kopetz S, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan H, Van Cutsem E, Ciardiello F, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chung C-H, Usari T, Nichols T, Murphy D, Tabernero J January 21, 2023 ASCO GI 2023 Colorectal Cancer

BREAKWATER Safety Lead-in (SLI): Encorafenib (E) + Cetuximab (C) + Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)

View Presentation
Poster
Wilson R, Vieira MC, Roach M, Prood N, Mesana L, Belani A, May SG January 21, 2023 ASCO GI 2023 Colorectal Cancer

Patient Perspectives on Colorectal Cancer Care Delivery During the COVID-19 Pandemic: A Qualitative Interview Study

View Presentation
Poster
Kopetz S, Bekaii-Saab T, Yoshino T, Chung C-H, Zhang X, Tabernero J January 21, 2023 ASCO GI 2023 Colorectal Cancer

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary